MedPath

Myopic Optic Neuropathy in Chinese High Myopia Population

Active, not recruiting
Conditions
Eye Diseases
Registration Number
NCT04302220
Lead Sponsor
Sun Yat-sen University
Brief Summary

This study intends to establish a registry cohort to enroll patients with high myopia to study the natural course of myopic optic neuropathy in Chinese adult population.

Detailed Description

Global prevalence of high myopia brings about markedly increasing of blinding complications as myopic optic neuropathy (MON) and glaucoma. It was estimated that there were 163 million people who have high myopia in 2000, and the population with high myopia would increase to almost one billion (9.8% of the world population) worldwide by 2050.

Glaucoma is the leading cause of irreversible blindness worldwide while it is difficult to distinguish glaucoma among MON in high myopia eyes. However, there lack longitudinal study to illustrate the natural course interpreting the distribution and natural history of MON.

In view of the above problems, this is a longitudinal registry cohort study to observe the long-term changes of structural and functional parameters of MON in high myopia, and to investigate the natural course and associted risk factors that influence the progression in a Chinese adult population.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
813
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Progression of glaucoma within 36 months3 years

Structural and functional changes of glaucoma using visual field, stereoscopic fundus photography.

Secondary Outcome Measures
NameTimeMethod
Progression of myopia and other structural changes of retina and choroid.3 years

Structural and functional changes of myopia based on axial length and refractive error.

Trial Locations

Locations (1)

Zhongshan Ophthalmic Center

🇨🇳

Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath